WO2021078835A1
2020-10-22
Pharmaceutical composition comprising selexipag
WO2021013815A1
2020-07-21
Methods of treating multiple sclerosis
WO2020249602A1
2020-06-10
Methods for treating pulmonary arterial hypertension
WO2020234361A2
2020-05-20
Transitioning patients treated for pulmonary arterial hypertension to selexipag
WO2020225297A1
2020-05-06
Methods for treating sarcoidosis-associated pulmonary hypertension
WO2020201479A1
2020-04-03
Macitentan for use in treating portopulmonary hypertension
TW202042818A
2020-01-22
Pharmaceutical composition for the treatment of chronic thromboembolic pulmonary hypertension
WO2020128017A1
2019-12-20
Pharmaceutical composition for the treatment of pulmonary arterial hypertension
AR115293A1
2019-12-20
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
CN112236424A
2019-06-05
Alkoxy-substituted pyridyl derivatives
PE20191489A1
2018-03-13
PHARMACEUTICAL COMBINATION INCLUDING PONESIMOD
TW201842910A
2018-03-06
Pharmaceutical composition comprising selexipag
US2018179196A1
2017-12-18
Crystalline forms of cadazolid
US2018125797A1
2017-11-06
Methods for treating skin disorders with a topical composition of bis-(2-chloroethyl)methylamine
TW201738239A
2017-04-13
Antibacterial biaromatic derivatives with oxetane-3-yloxy substitution
ZA201702615B
2017-04-12
Triazole compounds as t-type calcium channel blockers
CN108137596A
2016-09-02
1,2- dihydro -3H- pyrrolo-es [1,2-c] imidazoles -3- ketone antimicrobial compounds being substituted
TW201718484A
2016-08-26
Antibacterial annulated pyrrolidin-2-one derivatives
KR20180014832A
2016-06-21
NADPH oxidase 4 inhibitor
CN107667104A
2016-05-19
The crystal form of the glycol of compound (S) 3 { 4 [methylphenoxy of 5 (base of 2 cyclopenta, 6 methoxypyridine 4) [base of 1,2,4] oxadiazoles 3] 2 ethyl 6 } propane 1,2
